logo mainlogo darklogo main
  • HOME
  • ABOUT
    • Our Story
    • Quality
    • Clients
  • PRODUCTS
    • APIs
      • APIs List
      • Amisulpride
      • Bilastine
      • Bedaquiline
      • Ethopabate
      • Vonoprazan
      • Rivaroxaban
      • Metoclopramide
      • Carvedilol
      • Silodosin
      • Dapagliflozin
      • Empagliflozin
      • Oseltamivir Phosphate
      • Carglumic Acid
      • Tofacitinib Citrate
      • Posaconazole
      • Nirmatrelvir
      • Bumetanide
      • Brivaracetam
      • Resmetirom
    • Drug Intermediates
    • Biological
    • Reaction Capabilities
  • CSR
  • CONTACT
logo mainlogo darklogo main
  • HOME
  • ABOUT
    • Our Story
    • Quality
    • Clients
  • PRODUCTS
    • APIs
      • APIs List
      • Amisulpride
      • Bilastine
      • Bedaquiline
      • Ethopabate
      • Vonoprazan
      • Rivaroxaban
      • Metoclopramide
      • Carvedilol
      • Silodosin
      • Dapagliflozin
      • Empagliflozin
      • Oseltamivir Phosphate
      • Carglumic Acid
      • Tofacitinib Citrate
      • Posaconazole
      • Nirmatrelvir
      • Bumetanide
      • Brivaracetam
      • Resmetirom
    • Drug Intermediates
    • Biological
    • Reaction Capabilities
  • CSR
  • CONTACT
logo main logo darklogo light
  • HOME
  • ABOUT
    • Our Story
    • Quality
    • Clients
  • PRODUCTS
    • APIs
      • APIs List
      • Amisulpride
      • Bilastine
      • Bedaquiline
      • Ethopabate
      • Vonoprazan
      • Rivaroxaban
      • Metoclopramide
      • Carvedilol
      • Silodosin
      • Dapagliflozin
      • Empagliflozin
      • Oseltamivir Phosphate
      • Carglumic Acid
      • Tofacitinib Citrate
      • Posaconazole
      • Nirmatrelvir
      • Bumetanide
      • Brivaracetam
      • Resmetirom
    • Drug Intermediates
    • Biological
    • Reaction Capabilities
  • CSR
  • CONTACT
Brivaracetam API Regulatory Approvals: USFDA, EMA & WHO-GMP Compliance for Global Pharma Buyers
September 30, 2025
Uncategorized

Brivaracetam API Regulatory Approvals: USFDA, EMA & WHO-GMP Compliance for Global Pharma Buyers

Brivaracetam API Regulatory Approvals: USFDA, EMA & WHO-GMP Compliance for Global Pharma Buyers   Brivaracetam API is a next-generation antiepileptic drug rapidly gaining

Read More
Global Market Trends of Brivaracetam API: Opportunities for Bulk Procurement from India
September 30, 2025
Uncategorized

Global Market Trends of Brivaracetam API: Opportunities for Bulk Procurement from India

Global Market Trends of Brivaracetam API: Opportunities for Bulk Procurement from India   The global market trends of Brivaracetam API signal rising demand, driven by increasi

Read More
September 17, 2025
Uncategorized

The Future of Antidiabetic APIs: Role of Empagliflozin in Diabetes Care

The Future of Antidiabetic APIs: Role of Empagliflozin in Diabetes Care Empagliflozin is reshaping the future of antidiabetic APIs with its dual impact on glycemic control and card

Read More
September 17, 2025
Uncategorized

Empagliflozin API FAQs: Storage, Solubility, COA, and Manufacturing Standards

Empagliflozin API FAQs: Storage, Solubility, COA, and Manufacturing Standards Empagliflozin API is a critical compound used in the formulation of anti-diabetic drugs (SGLT2 inhibit

Read More
September 16, 2025
Uncategorized

Key Regulatory Guidelines for Empagliflozin API Exports to the EU & US

 Key Regulatory Guidelines for Empagliflozin API Exports to the EU & US Empagliflozin is a vital anti-diabetic Empagliflozin API increasingly in demand across regulated market

Read More
September 16, 2025
Uncategorized

Buyer’s Guide: How to Select the Right Empagliflozin API Supplier

Buyer’s Guide: How to Select the Right Empagliflozin API Supplier   Choosing the right Empagliflozin API supplier is critical for pharmaceutical manufacturers focused on the

Read More
September 16, 2025
Uncategorized

Pricing Factors of Empagliflozin API: What Impacts Cost in India?

Pricing Factors of Empagliflozin API: What Impacts Cost in India?   Empagliflozin API is a widely used anti-diabetic compound, and its cost is influenced by multiple factors.

Read More
Top Antidiabetic APIs in India: Empagliflozin, Metformin, Sitagliptin & More
September 15, 2025
Uncategorized

Top Antidiabetic APIs in India: Empagliflozin, Metformin, Sitagliptin & More

Top Antidiabetic APIs in India: Empagliflozin, Metformin, Sitagliptin & More India is among the top global producers of antidiabetic Active Pharmaceutical Ingredients (APIs), s

Read More
Empagliflozin vs Dapagliflozin APIs: Key Differences Pharma Buyers Should Know
September 12, 2025
Uncategorized

Empagliflozin vs Dapagliflozin APIs: Key Differences Pharma Buyers Should Know

Empagliflozin vs Dapagliflozin APIs: Key Differences Pharma Buyers Should Know   Empagliflozin and Dapagliflozin APIs are leading sodium-glucose co-transporter-2 (SGLT2) inhib

Read More
2025 Global Trends in Empagliflozin API Manufacturing
September 11, 2025
Uncategorized

2025 Global Trends in Empagliflozin API Manufacturing

2025 Global Trends in Empagliflozin API Manufacturing The global demand for Empagliflozin API, a leading SGLT2 inhibitor for Type 2 diabetes, is set to grow sharply through 2025. P

Read More

Posts pagination

01 02
Bio synth

Biochemical & Synthetic
Products Private Limited

About
  • Our Story
  • Quality
  • Clients
  • CSR
  • Blogs
Products
  • APIs
  • Advanced Drug Intermediates
  • Biological
  • Reaction Capabilities
  • Product Intermediates
APIs List
  • Bedaquiline
  • Bilastine
  • Vonoprazan
  • Amisulpride
  • Metoclopramide
  • Ethopabate
  • Rivaroxaban
  • Carvedilol
  • Silodosin
  • Dapagliflozin
  • Empagliflozin
  • Oseltamivir Phosphate
  • Carglumic Acid
  • Tofacitinib Citrate
  • Nirmatrelvir
  • Posaconazole
  • Bumetanide
  • Brivaracetam
  • Resmetirom
Contact

Plot No. 11/6/2029, Phase 2, S.V.C.I.E, Balanagar, Hyderabad - 500037, Telangana, India

+91 77997 74402 (India)

info@bio-synth.com

© 2024 All Rights Reserved

  • →
  • Contact Us
    Contact Us

  • Phone
  • WhatsApp